Samples of 27 drugs manufactured in Himachal found substandard

As many as 27 drug samples, manufactured at pharmaceutical units of Himachal Pradesh at Baddi, Nalagarh, Paonta Sahib, Kala Amb, Solan and Kangra, have been declared sub substandard by the Central Drugs Standard Control Organisation (CDSCO).

These figure among the list of 111 drug samples declared not of standard quality and the Central Drugs Standard Control Organization (CDSCO) has issued a drug alert regarding this.

The list released on December 27, is part of the continuous regulatory surveillance where drugs samples are picked from sales/distribution points and analysed.

CDSCO releases list of the medicines that do not meet the standards and in month of November a total of 111 drug samples failed. Out of these 27 drugs were manufactured in Himachal. Most of the these drugs are used in the treatment of heart diseases, high blood pressure, pain, antibiotics and other diseases, including allergies.

State drugs controller Manish Kapoor said they were closely regulating the manufacturing through regular inspections where compliance was ensured in firms lacking regulatory parameters.

He said about 142 companies have been ordered to stop manufacturing following certain flaws that were noticed during inspection. Kapoor said that action will be taken as per rules against the companies whose drug samples have failed. Notices have been issued to these drug companies.

Related Posts

Ministry declares PCI’s regulation on pharmacist recruitment, promotion and services as ultra vires

The ministry of health and family welfare has declared the Pharmacy Council of India’s (PCI) recently notified regulation on the pharmacist recruitment, promotion and services as ultra vires and does…

Second Documented Case of Pan-Drug Resistant Candida auris Uncovered in Kenya

NAIROBI/GENEVA— In an alarming development that underscores the accelerating global crisis of antimicrobial resistance, researchers have confirmed the detection of a rare, pan-drug resistant strain of the high-priority fungal pathogen…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Ministry declares PCI’s regulation on pharmacist recruitment, promotion and services as ultra vires

Ministry declares PCI’s regulation on pharmacist recruitment, promotion and services as ultra vires

Second Documented Case of Pan-Drug Resistant Candida auris Uncovered in Kenya

Second Documented Case of Pan-Drug Resistant Candida auris Uncovered in Kenya

AstraZeneca Pharma India opens new Mumbai corporate office, marking the next phase of growth through innovation

AstraZeneca Pharma India opens new Mumbai corporate office, marking the next phase of growth through innovation

Pharmaceuticals export reports around 4.9 per cent growth in H1 FY27

Pharmaceuticals export reports around 4.9 per cent growth in H1 FY27

NDLEA Intercepts Massive ₦6.98 Billion Tramadol Shipment Imported from India at Lagos Port

NDLEA Intercepts Massive ₦6.98 Billion Tramadol Shipment Imported from India at Lagos Port

Two More Pregnant Women In Rajasthan’s Kota Die From Kidney Complications

Two More Pregnant Women In Rajasthan’s Kota Die From Kidney Complications